Checkpoint inhibitor therapy in immunosuppressed patients with Merkel cell carcinoma: not all immunosuppression is created equal by Andrew S Brohl

Get full text

Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body rad... by Aasha I. Hoogland, Andrew S. Brohl, Brent J. Small, Lauren Michael, Evan Wuthrick, Zeynep Eroglu, Dukagjin Blakaj, Claire Verschraegen, Nikhil I. Khushalani, Heather S. L. Jim, Sungjune Kim

Get full text

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors by Howard Streicher, Elad Sharon, Mariano Severgnini, Michael Manos, Anita Giobbie-Hurder, F Stephen Hodi, Andrew S Brohl, Philippe L Bedard, Kevin Tyan, Scott Rodig, Osama E Rahma, Daniel J Renouf, Emma Hathaway, Rachel Cunningham

Get full text

Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes by Alex Soupir, Oscar E. Ospina, Oliver Hampton, Michelle Churchman, Michael Radmacher, Dale Hedges, David McKean, Phaedra Agius, Saman Zeeshan, Nathan D. Seligson, Raphael Pollock, David Liebner, James L. Chen, Gabriel Tinoco, Bodour Salhia, Martin McCarter, Breelyn A. Wilky, Benjamin J. Miller, Michael J. Cavnar, John S. Groundland, Bryan P. Schneider, Gregory Riedlinger, Stephen B. Edge, Christopher A. Moskaluk, Kenneth Cardona, Abdul Rafeh Naqash, Ricardo J. Gonzalez, John E. Mullinax, David M. Joyce, Odion Binitie, G. Douglas Letson, Arash O. Naghavi, Mihaela Druta, Damon R. Reed, Erin M. Siegel, Jamie K. Teer, Brooke L. Fridley, Andrew S. Brohl

Get full text